EGFR and non-small cell lung carcinoma: Meanwhile, in NSCLC, the activation of PAR2 leads to the reactivation of EGFR, which promotes the epithelial–mesenchymal transition (EMT) process of lung cancer cells through the ERK signaling pathway and then promotes the proliferation and migration of NSCLC cells (95).